Table 1 Distribution of BATMs and BTSMs compared to clinical and pathological parameters in our BC cohort
Parameters | Total | BATM-low | BATM-high | BTSM-low | BTSM-high |
|---|---|---|---|---|---|
Number of cases (%) | Number of cases (%) | Number of cases (%) | Number of cases (%) | Number of cases (%) | |
Age | |||||
≥ 50 years | 226 (75.8) | 123 (75.0) | 41 (25.0) | 31 (17.2) | 149 (82.3) |
<50 years | 72 (24.2) | 47 (83.9) | 9 (16.1) | 11 (16.7) | 51 (77.3) |
Chi-square p value | 0.169 | 0.926 | |||
Molecular subtype | |||||
Luminal A-like | 166 (55.7) | 99 (78.0) | 28 (22.0) | 37 (26.8) | 101 (73.2) |
Luminal B-like | 60 (20.1) | 39 (79.6) | 10 (20.4) | 2 (3.8) | 50 (96.2) |
Triple negative | 38 (12.8) | 16 (66.7) | 8 (33.3) | 0 (0.0) | 30 (100.0) |
HER2 amplified luminal-like | 24 (8.1) | 11 (78.6) | 3 (21.4) | 1 (6.3) | 15 (93.7) |
HER2 amplified non luminal-like | 8 (2.7) | 5 (83.3) | 1 (16.7) | 2 (33.3) | 4 (66.7) |
Chi square p value | 0.779 | 0.000011*** | |||
Grading | |||||
G1 | 15 (5) | 7 (63.6) | 4 (36.4) | 4 (30.8) | 9 (69.2) |
G2 | 103 (34.6) | 56 (77.8) | 16 (22.2) | 12 (15.0) | 68 (85.0) |
G3 | 44 (14.8) | 25 (78.1) | 7 (21.9) | 7 (20.6) | 27 (79.4) |
Chi-square p value | 0.594 | 0.337 | |||
Tumor foci | |||||
Unifocal | 161 (54.0) | 87 (74.4) | 30 (25.6) | 21 (16.0) | 110 (84.0) |
Multifocal/multicentric | 137 (46.0) | 83 (80.6) | 20 (19.4) | 21 (18.9) | 90 (81.1) |
Chi-square p value | 0.272 | 0.554 | |||
Tumor size | |||||
pT1 | 194 (65.1) | 114 (80.3) | 28 (19.7) | 31 (20.0) | 124 (80.0) |
pT2 | 87 (29.2) | 49 (75.4) | 16 (24.6) | 8 (11.1) | 64 (88.9) |
pT3 | 4 (1.3) | 1 (33.3) | 2 (66.7) | 0 (0.0) | 3 (100.0) |
pT4 | 13 (4.4) | 6 (60.0) | 4 (40.0) | 3 (25.0) | 9 (75.0) |
Chi-square p value | 0.094 | 0.276 | |||
Axillary lymph node status | |||||
pN0 | 164 (55.0) | 91 (77.8) | 26 (22.2) | 23 (17.6) | 108 (82.4) |
pN1 | 124 (41.6) | 73 (76.8) | 22 (23.2) | 18 (17.6) | 84 (82.4) |
pN2 | 4 (1.3) | 1 (33.3) | 2 (66.7) | 0 (0.0) | 4 (100.0) |
Chi-square p value | 0.224 | 0.796 | |||
ER status | |||||
Negative | 57 (19.1) | 28 (75.7) | 9 (24.3) | 4 (8.9) | 41 (91.1) |
Positive | 241 (80.9) | 142 (77.6) | 41 (22.4) | 38 (19.3) | 159 (80.7) |
Chi-square p value | 0.799 | 0.096 | |||
PR status | |||||
Negative | 128 (43.0) | 67 (75.3) | 22 (24.7) | 20 (25.0) | 80 (75.0) |
Positive | 170 (57.0) | 103 (78.6) | 28 (21.4) | 22 (15.5) | 120 (84.5) |
Chi-square p value | 0.561 | 0.362 | |||
HER2 status | |||||
Negative | 263 (88.3) | 154 (77.4) | 45 (22.6) | 39 (17.8) | 180 (82.2) |
Positive | 33 (11.1) | 16 (76.2) | 5 (23.8) | 3 (13.0) | 20 (87.0) |
Chi-square p value | 1.000 | 0.774 | |||
Expression of Ki-67 | |||||
≤ 14% | 167 (56.0) | 100 (78.1) | 28 (21.9) | 37(26.6) | 102 (73.4) |
>14% | 60 (20.1) | 39 (79.6) | 10 (20.4) | 2(3.8) | 50 (96.2) |
Chi-square p value | 0.832 | 0.001** | |||
Expression of EP3 | |||||
Low (IRS ≤ 1) | 87 (29.2) | 43 (68.3) | 20 (31.7) | 16 (22.2) | 56 (77.8) |
High (IRS >1) | 201 (67.4) | 124 (80.5) | 30 (19.5) | 26 (15.5) | 142 (84.5) |
Chi-square p value | 0.051 | 0.208 | |||